(Q36904879)

17 August 2017

1 reference

title

Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? (English)

1 reference

17 August 2017

Joanna K Soczynska

2

0 references

Roger S McIntyre

1

object named as

Roger S McIntyre

1 reference

17 August 2017

6

Glenda M MacQueen

1 reference

17 August 2017

author name string

Hanna O Woldeyohannes

3

1 reference

17 August 2017

Gary F Lewis

4

1 reference

17 August 2017

Lawrence A Leiter

5

1 reference

17 August 2017

Andrew Miranda

7

1 reference

17 August 2017

Don Fulgosi

8

1 reference

17 August 2017

Jakub Z Konarski

9

1 reference

17 August 2017

Sidney H Kennedy

10

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1615-1628

1 reference

The epidemiology of DSM-III-R bipolar I disorder in a general population survey.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Neurocognitive impairment in drug-free patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Cognitive deficits are associated with functional impairment in severely depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Brain activation measured with fMRI during a mental arithmetic task in schizophrenia and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Patterns of memory impairment in bipolar disorder and unipolar major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Executive dysfunction in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Cognitive generation of affect in bipolar depression: an fMRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Impairment of executive function but not memory in first-degree relatives of patients with bipolar I disorder and in euthymic patients with unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Neuroimaging studies of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Course of illness, hippocampal function, and hippocampal volume in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Neuroprotective agents in schizophrenia and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Stress and depression: possible links to neuron death in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Cognitive function over the treatment course of depression in middle-aged patients: correlation with brain MRI signal hyperintensities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Mood disorders and allostatic load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Stress and hippocampal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Stress-induced structural remodeling in hippocampus: prevention by lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Persistence of neuropsychologic deficits in the remitted state of late-life depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Agonists for Neurological Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Hippocampal atrophy in recurrent major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Glutamate and depression: clinical and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Insulin and neurodegenerative disease: shared and specific mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Short-term action of insulin onAplysia neurons: Generation of a possible novel modulator of ion channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Insulin receptors and insulin action in dissociated brain cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Inhibitory action of insulin on suprachiasmatic nucleus neurons in rat hypothalamic slice preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Peripheral hyperinsulinemia promotes tau phosphorylation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Signaling by insulin-like growth factor 1 in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Age-sensitive cognitive function, growth hormone and insulin-like growth factor 1 plasma levels in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

The relation between insulin-like growth factor I levels and cognition in healthy elderly: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Cognitive efficiency declines over time in adults with Type 1 diabetes: effects of micro- and macrovascular complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascular complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Cytokines and psychopathology: lessons from interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Cytokines sing the blues: inflammation and the pathogenesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Future therapeutic targets in mood disorders: the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Persistent cognitive impairment following surgical treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Decreased memory performance in healthy humans induced by stress-level cortisol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Antiglucocorticoid drugs in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Omega-3 fatty acids and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Ciglitazone increases basal cytokine expression in the central nervous system of adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Effects of peroxisome proliferator-activated receptor gamma ligands ciglitazone and 15-deoxy-delta 12,14-prostaglandin J2 on rat cultured cerebellar granule neuronal viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

Improving metabolic control leads to better working memory in adults with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1615

10.1517/14656566.8.11.1615

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference